<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236430</url>
  </required_header>
  <id_info>
    <org_study_id>P07551</org_study_id>
    <nct_id>NCT01236430</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)</brief_title>
  <official_title>A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With Marketed Products (Protocol No. P07551)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this study is to demonstrate that single doses of the Final Market Image (FMI)
      ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are
      bioequivalent to the same doses of ezetimibe (ZETIA®) and atorvastatin (LIPITOR®) that are
      coadministered as individual tablets in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time-curve from time zero to infinity (AUC0-∞) of atorvastatin</measure>
    <time_frame>Hour 0 to Hour 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of atorvastatin</measure>
    <time_frame>Hour 0 to Hour 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration time-curves from time zero to the time of last measured concentration (AUC0-last) of unconjugated ezetimibe (EZ)</measure>
    <time_frame>Hour 0 to Hour 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of unconjugated ezetimibe (EZ)</measure>
    <time_frame>Hour 0 to Hour 96</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10mg and Atorvastatin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe 10mg tablet and Atorvastatin 10mg tablet coadministered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg Ezetimibe/10mg Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg Ezetimibe/10mg atorvastatin combination tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10mg and Atorvastatin 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe 10mg tablet and Atorvastatin 80mg tablet coadministered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg Ezetimibe/80mg Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe/atorvastatin 10mg/80mg combination tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).</description>
    <arm_group_label>Ezetimibe 10mg and Atorvastatin 10mg</arm_group_label>
    <arm_group_label>Ezetimibe 10mg and Atorvastatin 80mg</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe/atorvastatin 10mg/10mg FDC</intervention_name>
    <description>Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).</description>
    <arm_group_label>10mg Ezetimibe/10mg Atorvastatin</arm_group_label>
    <other_name>SCH 900068</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).</description>
    <arm_group_label>Ezetimibe 10mg and Atorvastatin 10mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).</description>
    <arm_group_label>Ezetimibe 10mg and Atorvastatin 80mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe/atorvastatin 10mg/80mg FDC</intervention_name>
    <description>Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).</description>
    <arm_group_label>10mg Ezetimibe/80mg Atorvastatin</arm_group_label>
    <other_name>SCH 900068</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy adult males and females age 18-55 years

          -  Body mass index (BMI) between 18-35 kg/m^2

          -  Clinical laboratory tests (complete blood count, blood chemistry, and urinalysis),
             electrocardiogram, and vital signs must be within normal limits

          -  Must agree to refrain from consumption of red wine, grapefruit, and
             grapefruit-containing products, orange and apple juices, and orange- and
             apple-containing products from beginning approximately 2 weeks prior to administration
             of the initial dose of study drug, throughout the study (including the washout
             interval between treatment periods), and until the poststudy visit

        Exclusion Criteria

          -  Female subjects who are pregnant, intend to become pregnant (within 3 months of ending
             the study), or are nursing/breastfeeding.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of any drug

          -  History of any infectious disease within 4 weeks prior to drug administration

          -  Have demonstrated allergic reactions or hypersensitivities or intolerance to
             atorvastatin or other 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
             inhibitors, ezetimibe, or any component/excipient of the study drug or other food,
             drug, atopic reactions or asthmatic episodes which, in the opinion of the investigator
             and sponsor, interfere with their ability to participate in the trial.

          -  Have a history of prior myopathy or abnormality in liver function studies with statin
             therapy.

          -  Are positive for hepatitis B surface antigen, hepatitis C antibodies, or HIV.

          -  Have donated blood in the past 60 days

          -  Consume excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Seiberling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit AG, Lettenweg 118, CH-4123 Allschwil (Basel), Switzerland</affiliation>
  </overall_official>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2010</study_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>statin</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Zetia</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Lipitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

